CompletedNCT01258920
A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia
Medication studyAges 20+Japan
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 20 years. Other eligibility criteria applied.
- Listed locations
- Asahi and 28 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateOctober 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 201
- Sponsor
- Janssen Pharmaceutical K.K.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Japan
- Age range
- Over 20 Years
- Official registry ID
- NCT01258920
- Official title
Show the full official title
A Long-Term, Open-Label Study of Flexibly Dosed Paliperidone Palmitate Long-Acting Intramuscular Injection in Japanese Patients With Schizophrenia
Get this study by email
Recruitment & locations
CompletedAsahi · Fujioka · Fujisawa
26 more locations
- Hachiōji
- Higashimurayama
- Hiroshima
- Iizuka
- Kanuma
- Kashihara
- Kashiwara
- Kochi
- Kure
- Maebashi
- Moriguchi
- Nagasaki
- Nirasaki
- Ohta
- Sapporo
- Shimonoseki
- Shinjyuku
- Takatsuki
- Tama
- Tokushima
- Tokyo
- Ube
- Ueda
- Uji
- Yokohama
- Yokosuka
Questions about this study
Who is behind this study?
The study sponsor is Janssen Pharmaceutical K.K., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Paliperidone palmitate.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 20 years. Other eligibility criteria applied.
